World's Best Scientists 2026 revealed!
Alzheimer's Research and Therapy
H-index 62

Alzheimer's Research and Therapy

1758-9193

Published by: Springer

https://alzres.biomedcentral.com/

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Neuroscience 20 397 507 56
Medicine 204 396 488 53

Additional Metrics

Number of Best Scientists*: 989
Documents by Best Scientists*: 764
Top 100 Ranked Scientists*: 40
SCIMAGO H-index: 111
SCIMAGO SJR: 2.709
Impact Factor: 7.6

Overview

Top Research Topics at Alzheimer's Research & Therapy?

The journal primarily tackles Neurology, Dementia, Disease, Internal medicine and Geriatric psychiatry. The Neurology study featured falls within the wider field of Neuroscience. Neuroscience works presented in Alzheimer's Research & Therapy have a specific focus on Hippocampus.

The research on Dementia tackled can also make contributions to studies in the areas of Atrophy, Randomized controlled trial and Neuropsychology. Alzheimer's Research & Therapy explores topics in Disease which can be helpful for research in disciplines like Geriatrics gerontology and Clinical trial, Bioinformatics. The journal explores issues in Internal medicine which can be linked to other research areas like Endocrinology and Oncology.

Topics in Geriatric psychiatry were tackled in line with various other fields like Alternative medicine, Gerontology and Intensive care medicine. The Cognition works featured in it incorporate elements from Clinical psychology and Audiology. Research in the field of Pathology was used to conduct the presented Cerebrospinal fluid study.

  • Neurology (48.47%)
  • Dementia (35.95%)
  • Disease (33.87%)

What are the most cited papers published in the journal?

  • Alzheimer's disease drug-development pipeline: few candidates, frequent failures (1022 citations)
  • Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease (345 citations)
  • Recent global trends in the prevalence and incidence of dementia, and survival with dementia (340 citations)

Research areas of the most cited articles at Alzheimer's Research & Therapy:

The most cited articles focus largely on the fields of Disease, Neurology, Neuroscience, Dementia and Internal medicine. The journal articles address concerns in the field of Neurology by exploring it in line with topics in Cerebrospinal fluid which intersect with Amyloid subjects. The most cited publications explore topics in Dementia which can be helpful for research in disciplines like Psychiatry, Geriatric psychiatry, Epidemiology and Neuropsychology.

What topics the last edition of the journal is best known for?

  • Internal medicine
  • Gene
  • Disease

The previous edition focused in particular on these issues:

Alzheimer's Research & Therapy mostly deals with topics like Neurology, Dementia, Internal medicine, Disease and Cognitive decline. The concepts on Neurology presented in the journal can also apply to other research fields, including Cerebrospinal fluid, Atrophy, Pathology, Neuropsychology and Biomarker (medicine). The journal holds forums on Dementia that merges themes from other disciplines such as Cohort study, Geriatric psychiatry, Randomized controlled trial, Hazard ratio and Apolipoprotein E.

The study of Placebo and how it intertwines with concepts under Clinical endpoint were explored in the presented Internal medicine research. Disease research featured in the journal incorporates concerns from various other topics such as Bioinformatics, Immunology, Allele, Genetic association and Computational biology. While Cognitive decline is the focus of the journal, it also provided insights into the studies of Longitudinal study, Cognition, Neuroscience, Neurodegeneration and Amyloid.

The most cited articles from the last journal are:

  • Aducanumab produced a clinically meaningful benefit in association with amyloid lowering (21 citations)
  • A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. (21 citations)
  • A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. (15 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Alzheimer's Research & Therapy (based on the number of publications) are:

  • Philip Scheltens (66 papers) published 15 papers at the last edition, 5 more than at the previous edition,
  • Henrik Zetterberg (65 papers) published 12 papers at the last edition, 3 less than at the previous edition,
  • Kaj Blennow (62 papers) published 15 papers at the last edition, 3 more than at the previous edition,
  • Wiesje M. van der Flier (33 papers) published 7 papers at the last edition, 2 more than at the previous edition,
  • Charlotte E. Teunissen (33 papers) published 7 papers at the last edition the same number as at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Alzheimer's Research & Therapy (based on the number of publications) are:

  • University of Gothenburg (57 papers) published 12 papers at the last edition, 3 less than at the previous edition,
  • Lund University (51 papers) published 8 papers at the last edition, 1 less than at the previous edition,
  • Karolinska Institutet (50 papers) published 12 papers at the last edition, 3 more than at the previous edition,
  • Sahlgrenska University Hospital (50 papers) published 13 papers at the last edition the same number as at the previous edition,
  • VU University Amsterdam (48 papers) published 17 papers at the last edition, 6 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 0.56% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 28.49% were posted by at least one author from the top 10 institutions publishing in the journal. Another 11.73% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 24.58% of all publications and 35.20% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities in Alzheimer's Research

Studying Alzheimer's and related dementia disorders is not only critical for societal health but could also lead to numerous career opportunities in diverse research disciplines. Those interested in this field might consider becoming a speech therapist, a career that often intersects with Alzheimer's research - particularly when studying disease impact on a patient's communication abilities.

If you're passionate about Alzheimer's research and looking to make a difference, it might be worthwhile to consider becoming a speech therapist. This multidisciplinary role involves working with patients struggling with communication and swallowing disorders frequently seen in Alzheimer's disease progression.

You can explore more about the prerequisites required, necessary education, and the potential job pathway related to this career in our comprehensive guide on how to be a speech therapist in Delaware. Remember, breakthroughs in Alzheimer's research often come from diverse fields, so no matter your chosen discipline, there's always a way to contribute to the fight against this devastating disease.

Top Publications

  • Repurposed agents in the Alzheimer’s disease drug development pipeline

    Justin Bauzon;Garam Lee;Jeffrey Cummings;Jeffrey Cummings

    (2020)
    671 Citations
  • Immediate and long-term consequences of COVID-19 infections for the development of neurological disease.

    Michael T. Heneka;Michael T. Heneka;Douglas T. Golenbock;Eicke Latz;Eicke Latz;Dave Morgan

    (2020)
    573 Citations
  • A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

    Chad J. Swanson;Yong Zhang;Shobha Dhadda;Jinping Wang

    (2021)
    553 Citations
  • The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

    Martí Colom-Cadena;Tara Spires-Jones;Henrik Zetterberg;Kaj Blennow;Kaj Blennow

    (2020)
    331 Citations
  • Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.

    Martin Tolar;Susan Abushakra;John A. Hey;Anton Porsteinsson

    (2020)
    304 Citations
  • Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

    (2022)
    222 Citations

Related Online Degrees & Career Pathways

For those interested in expanding their healthcare knowledge beyond traditional medical degrees, several online programs offer flexible and affordable options. Aspiring healthcare administrators can explore the cheapest master's in healthcare administration, which equips students with leadership skills essential for managing healthcare facilities efficiently.

Nursing is another vital area with diverse career pathways. Prospective nurses might consider a 10 month LPN program that provides a fast-tracked entry into practical nursing roles, offering hands-on experience in a short period. For advanced nursing careers, pursuing one of the cheapest DNP programs online allows for specialization and leadership in clinical practice, policy, and healthcare education.

Additionally, the healthcare industry requires skilled administrative professionals. Online courses from the medical billing and coding online schools that accept financial aid make it accessible and affordable to train for essential roles that ensure smooth billing and compliance in medical settings.

Together, these programs offer a spectrum of options for students and professionals looking to enhance their careers in healthcare through flexible and financially viable online education pathways.

Best Scientists Contributing to This Journal

Recently Published Articles